Monday, March 12, 2007 9:41:25 AM
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—March 12, 2007--GenoMed (OTC Pink Sheets GMED.PK), the Next Generation Disease Management company whose business is public health™, announced today publication of a case report of a sickle cell patient whose pain has disappeared for over a year thanks to GenoMed's treatment.
The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication accidentally ran out on February 6, 2006. Said her physician, who is lead author on the case report, "Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin."
Her pain ceased within a few days of resuming GenoMed's treatment in February, 2006. In June, 2006, her physician intentionally stopped GenoMed's treatment to see what would happen. The patient's pain recurred within a week. When she resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for a total of 14 months now.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Although only a single patient, she satisfied a rigorous clinical test. As long as the patient was on our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. She hasn't needed pain pills in over a year; previously she took an average of four Vicodins a day. It doesn't get much more convincing than this."
Added Dr. Moskowitz, "We'd like to see if our results hold up with additional patients. Until now, there hasn't been effective treatment for sickle cell disease."
About GenoMed
GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including sickle cell disease. This case report was published in the March issue of the Journal of the National Medical Association (http://www.nmanet.org/images/uploads/Publications/CR0276.pdf). To enroll in GenoMed's sickle cell disease trial, please contact Dr. Moskowitz (see above).
Recent GMED News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:15:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 09:16:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 08:48:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/10/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/10/2024 04:11:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 08:11:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 07:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:21:08 PM
- Globus Medical Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/07/2024 08:15:00 PM
- Globus Medical Schedules First Quarter Earnings Release and Conference Call • GlobeNewswire Inc. • 04/16/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:07:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 11:50:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:35:42 PM
- Globus Medical Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 02/20/2024 09:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:08:54 PM
- Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call • GlobeNewswire Inc. • 02/13/2024 10:17:08 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 06:08:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:45:09 PM
- Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer • GlobeNewswire Inc. • 02/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:11:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:09:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:06:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:58:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:55:53 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM